Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$180.96 USD
+2.38 (1.33%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Charles River Laboratories' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Charles River Laboratories.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM
by Zacks Equity Research
Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM
6 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Design System, The Toro Company, Charles River Laboratories International and ICON
by Zacks Equity Research
Zacks.com featured highlights include: Design System, The Toro Company, Charles River Laboratories International and ICON
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Icon PLC (ICLR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River (CRL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories (CRL) Q3 Earnings Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 3.05% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Earnings Slated on Nov 6: HUM, ELAN & More
by Zacks Equity Research
Rise in senior population, shift of care to lower-cost settings and decline in unemployment are likely to have driven healthcare sector earnings.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Names Two Leaders for Major Business Wings
by Zacks Equity Research
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
What Makes Charles River (CRL) a New Buy Stock
by Zacks Equity Research
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories (CRL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 5.16% and -0.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
by Zacks Equity Research
Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.
Earnings Preview: Charles River Laboratories (CRL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Q1 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc's Partnership to Form Pediatric Telehealth Platform
by Zacks Equity Research
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
Top Ranked Growth Stocks to Buy for April 12th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 12th.
Charles River Laboratories (CRL) Is Up 2.99% in One Week: What You Should Know
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.